We are live on ! Find out more
ATNM icon

Actinium Pharmaceuticals
ATNM

42 hedge funds and large institutions have $7.05M invested in Actinium Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 8

17% more funds holding

Funds holding: 36 → 42 (+6)

0.35% less ownership

Funds ownership: 0.68% → 0.33% (-0.35%)

14% less capital invested

Capital invested by funds: $8.22M → $7.05M (-$1.17M)

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

Holders
42
Holders Change
+6
Holders Change %
+16.67%
% of All Funds
0.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
6
Reduced
8
Closed
8
Calls
$32K
Puts
–
Net Calls
+$32K
Net Calls Change
-$394K

Top Buyers

Rank Fund Capital Flow
1
CS
Credit Suisse
Switzerland
+$211K
2
Renaissance Technologies
Renaissance Technologies
New York
+$152K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$51.2K
4
CAN
Cetera Advisor Networks
California
+$50.9K
5
Deutsche Bank
Deutsche Bank
Germany
+$37.9K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$2.23M
2
AFM
Anson Funds Management
Texas
-$1.5M
3
SM
Sabby Management
Florida
-$729K
4
DAM
DLD Asset Management
New York
-$106K
5
SCM
Sio Capital Management
New York
-$86.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
VFA
26
Valeo Financial Advisors
Indiana
$19K – – –
Jacobs Levy Equity Management
27
Jacobs Levy Equity Management
New Jersey
$18K +$12.1K +953 New
SFG
28
SNS Financial Group
Minnesota
$17K – – –
BFM
29
Boothbay Fund Management
New York
$16K +$10.9K +859 New
DY
30
Dowling & Yahnke
California
$15K – – –
Squarepoint
31
Squarepoint
New York
$14K +$9.41K +743 New
IB
32
Intrust Bank
Kansas
$13K +$8.45K +667 New
HFM
33
Hartford Financial Management
Connecticut
$12K – – –
RJFSA
34
Raymond James Financial Services Advisors
Florida
$11K – – –
Morgan Stanley
35
Morgan Stanley
New York
$10K -$127 -10 -2%
State Street
36
State Street
Massachusetts
$8K – – –
TSS
37
Two Sigma Securities
New York
$7K +$4.84K +382 New
BEAM
38
Baker Ellis Asset Management
Washington
$6K – – –
WS
39
Wedbush Securities
California
$6K +$4.22K +333 New
CF
40
Centaurus Financial
California
$2K +$1.23K +97 New
Bank of America
41
Bank of America
North Carolina
$1K – – –
FIA
42
FNY Investment Advisers
New York
$1K +$849 +67 New
AC
43
Armistice Capital
New York
– -$2.23M -203,333 Closed
AFM
44
Anson Funds Management
Texas
– -$1.5M -137,130 Closed
SM
45
Sabby Management
Florida
– -$729K -66,590 Closed
DZ Bank
46
DZ Bank
Germany
– -$41K -3,752 Closed
Goldman Sachs
47
Goldman Sachs
New York
– -$11K -981 Closed
Ameriprise
48
Ameriprise
Minnesota
– -$5K -500 Closed
UBS Group
49
UBS Group
Switzerland
– -$1K -114 Closed
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
– -$1K -82 Closed
1
2

ATNM Hedge Fund Activity: Q2 2018 in Review

42 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q2 2018, worth a combined $7.05M — down 14% from $8.22M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new ATNM positions and 8 closed out — a net gain of 6 holders — while 6 added to existing stakes and 8 trimmed.

The largest buyer was Credit Suisse, adding an estimated $211K. The largest seller was Armistice Capital, exiting entirely with an estimated $2.23M sold.

  • 42 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q2 2018, up from 36 in Q1 2018.
  • Funds reported $7.05M of Actinium Pharmaceuticals stock for Q2 2018, down 14% quarter-over-quarter.
  • 14 funds opened new Actinium Pharmaceuticals positions in Q2 2018 and 8 closed out, a net change of +6 holders.
  • The largest Actinium Pharmaceuticals buyer in Q2 2018 was Credit Suisse, an estimated $211K added.
  • The largest Actinium Pharmaceuticals seller in Q2 2018 was Armistice Capital, an estimated $2.23M sold.

Based on aggregated 13F filings for Q2 2018.